Chlorphenamine

Revision as of 18:57, 27 September 2011 by WikiBot (talk | contribs) (Protected "Chlorphenamine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Chlorphenamine
Clinical data
Pregnancy
category
  • AU: A
  • US: B (No risk in non-human studies)
Routes of
administration
Oral, IV, IM, SC
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability25 to 50%
Protein binding72%
MetabolismHepatic (CYP2D6)
Elimination half-life21-27 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC16H19ClN2
Molar mass274.788 g/mol
Solubility in water0.55 g/100 mL, liquid mg/mL (20 °C)

Chlorphenamine (INN) or chlorpheniramine (USAN, former BAN), commonly marketed as its salt chlorphenamine maleate (CPM; Chlor-Trimeton®, Piriton®, Chlor-Tripolon®), is a first-generation antihistamine used in the prevention of the symptoms of allergic conditions such as rhinitis and urticaria. Its sedative effects are relatively weak compared to other first-generation antihistamines.

Chlorphenamine has antidepressant properties, inhibiting reuptake of the neurotransmitter serotonin. Based on this knowledge, the Swedish company Astra AB was able to derive the first marketed selective serotonin reuptake inhibitor, zimelidine, from chlorphenamine.

See also

File:DSC000776.JPG
Chlorphenamine 4mg from U.K.

References